Advertisement
Advertisement
U.S. markets open in 4 hours 1 minute
S&P Futures
3,829.25 +3.75 (+0.10%) Dow Futures
30,982.00 +49.00 (+0.16%) Nasdaq Futures
11,686.50 +12.25 (+0.10%) Russell 2000 Futures
1,740.10 +1.80 (+0.10%) Crude Oil
112.16 +0.40 (+0.36%) Gold
1,818.70 -2.50 (-0.14%)
NeuroPace, Inc. (NPCE)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 5.36 |
| Open | 5.45 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 5.12 - 5.70 |
| 52 Week Range | 4.61 - 25.26 |
| Volume | |
| Avg. Volume | 72,325 |
| Market Cap | 125.979M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for NPCE
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Neuropace, Inc.Analyst Report: LivaNova PLCU.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management segment. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.RatingFair ValueEconomic Moat5 days agoMorningstar
- Simply Wall St.
Shareholders in NeuroPace (NASDAQ:NPCE) are in the red if they invested a year ago
Even the best stock pickers will make plenty of bad investments. Anyone who held NeuroPace, Inc. ( NASDAQ:NPCE ) over...
- Motley Fool
NeuroPace, Inc. (NPCE) Q1 2022 Earnings Call Transcript
Joining me from NeuroPace are Mike Favet, CEO; and Rebecca Kuhn, CFO. Earlier today, NeuroPace released financial results for the first quarter ended March 31, 2022. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- Zacks
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
